U S Physical Therapy Inc /Nv (USPH) Stock Analysis and Metrics

U S Physical Therapy

NYSE: USPH

$73.72 ▼ -0.47 (-0.63%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.08 Bn

P/E20.50

P/S1.36

Div. Yield0.02

ROIC (Qtr)0.00

Total Debt (Qtr)6.34 Mn

Revenue Growth (1y) (Qtr)7.89

Add ratio to table…

About

U. S. Physical Therapy, Inc. operates outpatient physical therapy clinics and provides industrial injury prevention services across the United States. The company delivers physical, speech and occupational therapy through clinic partnerships and wholly owned facilities, and offers on site injury prevention, performance testing and ergonomic assessments to employers. Revenue is generated primarily from patient service payments received from managed care organizations,…

Investment Thesis

▲ Bull case

US Physical Therapy's strategic hospital partnerships, particularly the NYU and Gulf Coast initiatives, represent a significantly underappreciated growth catalyst that could substantially accelerate EBITDA generation in the back half of 2026 and beyond, as management indicated these affiliations will begin delivering material quarterly run-rate impacts by Q4 2026, with the potential to capture high-margin volumes from large institutional networks that are currently not reflected in guidance. The company's ownership stakes in these partnerships (50% in NYU, with higher equity in other opportunities) allow for scalable replication where full control amplifies earnings contribution, and the pipeline includes opportunities exceeding NYU's scale, suggesting a multi-year runway for inpatient-to-outpatient referral volume growth that could drive same-store visit increases well above the current 2.5% Q1 trend, especially as de novo clinic openings in these systems add incremental capacity without the drag of greenfield startup costs.
The expansion of cash-based programs, including laser therapy, shockwave treatment, and dry needling, is gaining meaningful traction across top partnerships and represents a high-margin, self-pay revenue stream that is insulated from payer reimbursement volatility and Medicare/Medicaid rate risks, with partners already generating hundreds of thousands of dollars annually from zero baseline, and the initiative being actively promoted at partner meetings as a key differentiator; this not only diversifies revenue away from traditional insurance-dependent PT but also enhances patient retention and clinician engagement through clinically effective, cash-reimbursed services that improve unit economics and could lift net revenue per visit beyond the current $106.49 as these services scale, particularly in markets with strong demand for wellness and performance optimization services.
The company's disciplined capital allocation—evidenced by the recent $14 million investment to increase ownership in high-performing partnerships and the successful upsizing of its credit facility to $450 million with improved terms—provides substantial dry powder for both tuck-in acquisitions and strategic partner buyouts, enabling USPH to consolidate control in its most profitable relationships without compromising balance sheet strength, and this approach, combined with sub-18% turnover rates (the lowest in company history), supports sustainable same-store growth by retaining top clinicians and reducing recruitment/training costs, which directly counters margin pressure from wage inflation and positions the business to leverage operating leverage as visit volumes normalize post-weather headwinds in Q2 and beyond.
Despite Q1 GAAP earnings being negatively impacted by non-cash revaluation of redeemable noncontrolling interest and contingent earnout liabilities—both of which are accounting artifacts reflecting strong underlying performance in recent acquisitions—the core operational metrics remain robust, with adjusted EBITDA growing $700k year-over-year to $20.2 million in Q1, physical therapy revenue up 7.2%, and IIP margin expanding 180 basis points to 20.4%, indicating that the business is successfully executing its dual-segment strategy and that the market may be overemphasizing volatile GAAP earnings while underestimating the steady, cash-generative power of its mature clinic base and growing industrial injury prevention division, which benefits from recurring corporate contracts and less discretionary spending sensitivity.

US Physical Therapy's strategic hospital partnerships, particularly the NYU and Gulf Coast initiatives, represent a significantly underappreciated growth catalyst that could substantially accelerate EBITDA generation in the back half of 2026 and beyond, as management indicated these affiliations will begin delivering material quarterly run-rate impacts by Q4 2026, with the potential to capture high-margin volumes from large institutional networks that are currently not reflected in guidance. The company's ownership stakes in these partnerships (50% in NYU, with higher equity in other opportunities) allow for scalable replication where full control amplifies earnings contribution, and the pipeline includes opportunities exceeding NYU's scale, suggesting a multi-year runway for inpatient-to-outpatient referral volume growth that could drive same-store visit increases well above the current 2.5% Q1 trend, especially as de novo clinic openings in these systems add incremental capacity without the drag of greenfield startup costs.
The expansion of cash-based programs, including laser therapy, shockwave treatment, and dry needling, is gaining meaningful traction across top partnerships and represents a high-margin, self-pay revenue stream that is insulated from payer reimbursement volatility and Medicare/Medicaid rate risks, with partners already generating hundreds of thousands of dollars annually from zero baseline, and the initiative being actively promoted at partner meetings as a key differentiator; this not only diversifies revenue away from traditional insurance-dependent PT but also enhances patient retention and clinician engagement through clinically effective, cash-reimbursed services that improve unit economics and could lift net revenue per visit beyond the current $106.49 as these services scale, particularly in markets with strong demand for wellness and performance optimization services.
The company's disciplined capital allocation—evidenced by the recent $14 million investment to increase ownership in high-performing partnerships and the successful upsizing of its credit facility to $450 million with improved terms—provides substantial dry powder for both tuck-in acquisitions and strategic partner buyouts, enabling USPH to consolidate control in its most profitable relationships without compromising balance sheet strength, and this approach, combined with sub-18% turnover rates (the lowest in company history), supports sustainable same-store growth by retaining top clinicians and reducing recruitment/training costs, which directly counters margin pressure from wage inflation and positions the business to leverage operating leverage as visit volumes normalize post-weather headwinds in Q2 and beyond.
Despite Q1 GAAP earnings being negatively impacted by non-cash revaluation of redeemable noncontrolling interest and contingent earnout liabilities—both of which are accounting artifacts reflecting strong underlying performance in recent acquisitions—the core operational metrics remain robust, with adjusted EBITDA growing $700k year-over-year to $20.2 million in Q1, physical therapy revenue up 7.2%, and IIP margin expanding 180 basis points to 20.4%, indicating that the business is successfully executing its dual-segment strategy and that the market may be overemphasizing volatile GAAP earnings while underestimating the steady, cash-generative power of its mature clinic base and growing industrial injury prevention division, which benefits from recurring corporate contracts and less discretionary spending sensitivity.

▼ Bear case

US Physical Therapy's guidance of $102 million to $106 million in adjusted EBITDA for FY 2026 appears increasingly difficult to achieve given that Q1 contributed only $20.2 million, or approximately 19% of the midpoint guidance, implying a required run-rate of over $20.5 million per quarter for the remainder of the year—a level not sustained since pre-2023 and challenging to reach without meaningful acceleration from hospital initiatives or acquisitions, especially as the company acknowledged that the full annualized $7 million impact from NYU and Gulf Coast partnerships will not be realized until Q4 2026, meaning only a fraction of that benefit will flow through in 2026, and with weather-related visit losses already baked into Q1 results, the business faces a steep uphill climb to meet guidance absent a sharp, unanticipated rebound in volume growth beyond the current 6.9% year-over-year increase in total visits.
The company's reliance on commercial payer strength—representing nearly 50% of its payer mix and driving the 3.4% year-over-year increase in commercial revenue per visit—exposes it to significant risk if employment-linked insurance enrollment softens or if commercial payers intensify utilization management efforts, particularly as Medicare patients continue to exhibit delayed payment patterns at the start of the year due to deductible resets, creating a lag in realizing the full 1.75% Medicare rate increase, and with Medicaid rates showing regional weakness that could persist, the blended net revenue per visit growth remains fragile and highly dependent on the continued strength of commercial payer contracts, which are subject to annual renegotiation and could face downward pressure in a tightening macroeconomic environment.
Rising operating costs, particularly in adjusted physical therapy operating costs per visit which increased to $90.31 from $88.77 year-over-year, coupled with increased adjusted corporate expense as a percentage of revenue (8.8% vs. 8.5%), signal persistent cost inflation pressures that are not being fully offset by volume growth or efficiency gains, and while management attributes some of this to upfront investments in AI documentation and semi-virtualization, the lack of clear margin expansion in the core PT segment—where adjusted margin contracted from 16.8% to 16.1%—suggests that initiatives like ambient listening and remote therapeutic monitoring may take longer to deliver productivity gains than anticipated, leaving the business vulnerable to wage growth outpacing reimbursement increases, especially in high-cost markets like New York where weather-related disruptions disproportionately impacted high-net-rate visits.
The aggressive use of balance sheet capacity to fund acquisitions and increase ownership in partnerships—evidenced by $204 million in borrowings (up from $162 million) and $14 million in noncontrolling interest purchases—while strategically sound, increases financial leverage and interest expense (which rose to $2.8 million from $2.3 million), and with the Workday ERP implementation not expected to go live until end of 2027, the company is shouldering near-term integration and system modernization costs without the counterbalancing efficiency benefits, creating a scenario where incremental EBITDA from growth investments must not only justify the capital deployed but also overcome higher financing costs and ongoing SG&A drag, raising the bar for accretive returns on deployed capital in an environment where same-store revenue growth remains modest at 2.5%.

US Physical Therapy's guidance of $102 million to $106 million in adjusted EBITDA for FY 2026 appears increasingly difficult to achieve given that Q1 contributed only $20.2 million, or approximately 19% of the midpoint guidance, implying a required run-rate of over $20.5 million per quarter for the remainder of the year—a level not sustained since pre-2023 and challenging to reach without meaningful acceleration from hospital initiatives or acquisitions, especially as the company acknowledged that the full annualized $7 million impact from NYU and Gulf Coast partnerships will not be realized until Q4 2026, meaning only a fraction of that benefit will flow through in 2026, and with weather-related visit losses already baked into Q1 results, the business faces a steep uphill climb to meet guidance absent a sharp, unanticipated rebound in volume growth beyond the current 6.9% year-over-year increase in total visits.
The company's reliance on commercial payer strength—representing nearly 50% of its payer mix and driving the 3.4% year-over-year increase in commercial revenue per visit—exposes it to significant risk if employment-linked insurance enrollment softens or if commercial payers intensify utilization management efforts, particularly as Medicare patients continue to exhibit delayed payment patterns at the start of the year due to deductible resets, creating a lag in realizing the full 1.75% Medicare rate increase, and with Medicaid rates showing regional weakness that could persist, the blended net revenue per visit growth remains fragile and highly dependent on the continued strength of commercial payer contracts, which are subject to annual renegotiation and could face downward pressure in a tightening macroeconomic environment.
Rising operating costs, particularly in adjusted physical therapy operating costs per visit which increased to $90.31 from $88.77 year-over-year, coupled with increased adjusted corporate expense as a percentage of revenue (8.8% vs. 8.5%), signal persistent cost inflation pressures that are not being fully offset by volume growth or efficiency gains, and while management attributes some of this to upfront investments in AI documentation and semi-virtualization, the lack of clear margin expansion in the core PT segment—where adjusted margin contracted from 16.8% to 16.1%—suggests that initiatives like ambient listening and remote therapeutic monitoring may take longer to deliver productivity gains than anticipated, leaving the business vulnerable to wage growth outpacing reimbursement increases, especially in high-cost markets like New York where weather-related disruptions disproportionately impacted high-net-rate visits.
The aggressive use of balance sheet capacity to fund acquisitions and increase ownership in partnerships—evidenced by $204 million in borrowings (up from $162 million) and $14 million in noncontrolling interest purchases—while strategically sound, increases financial leverage and interest expense (which rose to $2.8 million from $2.3 million), and with the Workday ERP implementation not expected to go live until end of 2027, the company is shouldering near-term integration and system modernization costs without the counterbalancing efficiency benefits, creating a scenario where incremental EBITDA from growth investments must not only justify the capital deployed but also overcome higher financing costs and ongoing SG&A drag, raising the bar for accretive returns on deployed capital in an environment where same-store revenue growth remains modest at 2.5%.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password